Janice M. Mehnert, MD
Associate Professor of Medicine, Medical Oncology
Rutgers Cancer Institute of New Jersey
Phone: (732) 235-6080
Assistant: Pat Walker
Research Program Alignments
- Clinical Investigations Program
Membership Type: Associate - CCSG
- Developmental Therapeutics
- Sonic Hedgehog
- Transforming Growth Factor-Beta
- Solid Tumors
Hill JM, Mehnert J, McCune SK and Brenneman DE. Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides; 23(10):1803-8, Oct. 2002.
Yip D, Le M, Chan J-L, Lee JH, Mehnert JM, Yudd A, Kempf JS, Shih WJ, Chen S, and Goydos JS. A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma. Clin Cancer Res Jun 1;15(11):3896-902, 2009.
Mehnert JM, McCarthy MM, Aziz SA, Flaherty KT, Camp RL, Rimm DL, Kluger HM. Quantitative Expression of VEGF, VEGF-R1, VEGF-R2 and VEGF-R3 in Melanoma Tissue Microarrays. Human Pathology, 2010 Mar; 41(3):375-84, 2009.
Saraiya B, Chugh R, Karantza V, Mehnert J, Moss RA, Savkina N, Stein MN, Baker LH, Chenevert T, Poplin EA. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, Feb;30(1):258-65. 2010.
Khan A, Wall BA, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG. Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo. Clin Cancer Research, Apr 1;17(7):1807-14, 2011.
Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, and Karantza V. Rationally designed treatment for solid tumors with MAPK pathway activation: a Phase I study of paclitaxel and bortezomib in patients with advanced solid malignancies using an adaptive dose-finding approach. Mol Cancer Ther. Aug;10(8):1509-19, 2011.